Table 4.
Results of trials with CAR-T post-HSCT. Abbreviations: CR: complete remission, PR: partial remission, CRi: complete remission with incomplete hematologic recovery, MLFR: myeloid leukemia free state, no resp: no response, SD: stable disease.
| Authors | Target | CAR Construct | n. pts | Best Response |
|---|---|---|---|---|
| Ritchie, 2013 [154] | CD33 | CD28-CD3 | 4 | 1 CR 1 PR |
| Wang, 2015 [155] | CD 33 | 4-1BB | 1 | 1 PR |
| Tang, 2018 [156] | CD 33 | CD28-4-1BB | 3 | 1 CR |
| Yao, 2019 [157] | CD 123 | 4-1BB | 1 | 1 CRi |
| Cummins, 2019 [158] | CD 123 | CD28-CD3 | 1 CR | |
| Zhang, 2021 [152] | CCL-1 | NR | 3 | 3 CR |
| Baumeister, 2013 [159] | NKG2D-L | CD3 | 7 | 7 No resp |
| Sallman, 2020 [160] | NKG2D-L | CD3 | 22 | 1 MLFR 1 PR 6 SD 14 no resp |
| Danylesko, 2020 [161] | CD19 | CD28 | 1 | 1 CR |
| Liu F, 2021 [EHA 2020] [162] | CLL-1–CD33 | NR | 9 | 7 CR |
| Tambaro, 2021 [163] | CD33 | 4-1BB | 10 | No resp |
| Budde LE, 2019 (EHA CAR-T 2019) [164] | CD123 | 4-1BB mRNA vector |
5 | 5 No resp |
| Deeren, 2021 [ASH 2020] [165] | NKG2D-L | CD3 | 2 | 1 SD 1 no resp |
| Total | 75 | 17 CR/CRi/CRh |